Literature DB >> 2537373

Arginine vasopressin, but not corticotropin releasing factor, is a potent stimulator of adrenocorticotropic hormone following electroconvulsive treatment.

E Widerlöv1, R Ekman, L Jensen, L Borglund, K Nyman.   

Abstract

Neuroendocrine responses to the hypothalamic pituitary-adrenal axis following electroconvulsive treatment (ECT) were evaluated in twelve depressed (6 males/6 females) patients. Plasma concentrations of arginine vasopressin (AVP), corticotropin releasing factor (CRF), corticotropin (ACTH), and cortisol were measured using radioimmunological methods at four different ECT occasions. At each occasion plasma samples were taken immediately before ECT, at the recovery of spontaneous breathing and at 10 and 30 minutes after the ECT. No changes were observed in the plasma CRF concentrations. A large and rapid increase in plasma AVP concentrations was seen after the ECTs. This was followed by increased plasma ACTH and plasma cortisol levels. It is generally believed that AVP exerts a modulatory potentiating action on the CRF-induced ACTH release. The present results demonstrate that AVP per se can cause a release of ACTH from the anterior pituitary.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537373     DOI: 10.1007/bf01677423

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  30 in total

1.  Corticotropin release during ECT in man.

Authors:  J P Allen; D Denney; J W Kendall; P H Blachly
Journal:  Am J Psychiatry       Date:  1974-11       Impact factor: 18.112

2.  Electroconvulsive therapy (ECT) increases plasma growth hormone, prolactin, luteinising hormone and follicle-stimulating hormone but not thyrotropin or substance P.

Authors:  P Skrabanek; A Balfe; M Webb; J Maguire; D Powell
Journal:  Psychoneuroendocrinology       Date:  1981       Impact factor: 4.905

3.  Serotonin and adrenocorticotropin (ACTH) release: direct effects at the anterior pituitary level and potentiation of arginine vasopressin-induced ACTH release.

Authors:  E Spinedi; A Negro-Vilar
Journal:  Endocrinology       Date:  1983-04       Impact factor: 4.736

4.  Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin.

Authors:  C Rivier; W Vale
Journal:  Nature       Date:  1983 Sep 22-28       Impact factor: 49.962

5.  Prolactin changes during electroconvulsive therapy.

Authors:  J P O'Dea; D Gould; M Hallberg; R G Wieland
Journal:  Am J Psychiatry       Date:  1978-05       Impact factor: 18.112

6.  Beta-adrenergic stimulation induces an increase of the plasma levels of immunoreactive alpha-MSH, beta-endorphin, ACTH and of corticosterone.

Authors:  F Berkenbosch; I Vermes; R Binnekade; F J Tilders
Journal:  Life Sci       Date:  1981-11-30       Impact factor: 5.037

7.  Interactions between CRF, epinephrine, vasopressin and glucocorticoids in the control of ACTH secretion.

Authors:  F Labrie; V Giguere; L Proulx; G Lefevre
Journal:  J Steroid Biochem       Date:  1984-01       Impact factor: 4.292

8.  Plasma immunoreactive beta-endorphin levels in depression. Effect of electroconvulsive therapy.

Authors:  G S Alexopoulos; C E Inturrisi; R Lipman; R Frances; J Haycox; J H Dougherty; J Rossier
Journal:  Arch Gen Psychiatry       Date:  1983-02

9.  A new sensitive radioimmunoassay for plasma arginine vasopressin.

Authors:  P Rooke; P H Baylis
Journal:  J Immunoassay       Date:  1982

10.  Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients.

Authors:  C B Nemeroff; E Widerlöv; G Bissette; H Walléus; I Karlsson; K Eklund; C D Kilts; P T Loosen; W Vale
Journal:  Science       Date:  1984-12-14       Impact factor: 47.728

View more
  1 in total

1.  Influence of cysteamine and cysteine on open-field behaviour, and on brain concentrations of catecholamines, somatostatin, neuropeptide Y, and corticotropin releasing hormone in the rat.

Authors:  L Vécsei; R Ekman; C Alling; E Widerlöv
Journal:  J Neural Transm Gen Sect       Date:  1989
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.